A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients
Launched by GLAXO WELLCOME · Aug 30, 2001
Trial Information
Current as of July 04, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- Patients must have:
- • HIV infection with CD4 counts = or \> 100 cells/mm3.
- • Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years.
- • History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study.
- • Exclusion Criteria
- Co-existing Condition:
- Patients with the following symptoms and conditions are excluded:
- • Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy.
- Concurrent Medication:
- Excluded:
- • Systemic antiherpes medication.
- • Interferon.
- Patients with the following prior conditions are excluded:
- • History of hypersensitivity to acyclovir.
About Glaxo Wellcome
Glaxo Wellcome, a leading global biopharmaceutical company, is dedicated to advancing healthcare through innovative research and development of new therapies. With a strong focus on addressing unmet medical needs, Glaxo Wellcome combines scientific excellence with a commitment to improving patient outcomes across various therapeutic areas, including respiratory, infectious diseases, and oncology. The company is recognized for its robust clinical trial portfolio, leveraging cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. Glaxo Wellcome upholds the highest ethical standards in clinical research, ensuring patient safety and integrity throughout the trial process.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Los Angeles, California, United States
New York, New York, United States
New York, New York, United States
Chicago, Illinois, United States
Washington, District Of Columbia, United States
Atlanta, Georgia, United States
Washington, District Of Columbia, United States
San Francisco, California, United States
San Francisco, California, United States
New York, New York, United States
Philadelphia, Pennsylvania, United States
Memphis, Tennessee, United States
Washington, District Of Columbia, United States
Washington, District Of Columbia, United States
Wichita, Kansas, United States
Galveston, Texas, United States
Atlanta, Georgia, United States
Portland, Oregon, United States
Baltimore, Maryland, United States
Rochester, New York, United States
Mobile, Alabama, United States
Tucson, Arizona, United States
St. Paul, Minnesota, United States
San Francisco, California, United States
Indianapolis, Indiana, United States
Orange, California, United States
West Haven, Connecticut, United States
Chicago, Illinois, United States
Jackson, Mississippi, United States
Providence, Rhode Island, United States
Kansas City, Missouri, United States
Richmond, Virginia, United States
San Diego, California, United States
Los Angeles, California, United States
Oakland, California, United States
San Diego, California, United States
St. Petersburg, Florida, United States
Iowa City, Iowa, United States
St. Louis, Missouri, United States
Pittsburgh, Pennsylvania, United States
Dallas, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Nassau Bay, Texas, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials